Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies.

Rhapsido (remibrutinib) - Novartis

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies. (PubMed, Clin Exp Allergy) - Oct 19, 2026 - No abstract available
Journal • P3 data • Retrospective data • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

http://www.ncbi.nlm.nih.gov/pubmed/42893886

Ana Maria Giménez-Arnau; Ansgar Weyergraf; Atsushi Fukunaga; Bin Yang; Christine-Elke Ortmann; El-Djouher Martzloff; Giselle Mosnaim; Gordon Sussman; Hui Tang; John Reed; Mark Lebwohl; Michihiro Hide; Nadine Chapman-Rothe; Paula G P Machado; Petra Staubach; Tao Ding

Oct 19, 2026